About this Journal Submit a Manuscript Table of Contents
Cardiovascular Psychiatry and Neurology
Volume 2013 (2013), Article ID 247486, 15 pages
http://dx.doi.org/10.1155/2013/247486
Clinical Study

Risk of Mortality (Including Sudden Cardiac Death) and Major Cardiovascular Events in Atypical and Typical Antipsychotic Users: A Study with the General Practice Research Database

1Clinical Practice Research Datalink, Medicines and Healthcare Products Regulatory Agency, London SWIW 9SZ, UK
2Eli Lilly and Company, Indianapolis, IN, USA
3London School of Hygiene & Tropical Medicine, London, UK
4Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands

Received 12 February 2013; Revised 27 August 2013; Accepted 8 October 2013

Academic Editor: Dominique L. Musselman

Copyright © 2013 Tarita Murray-Thomas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. A. Ray, S. Meredith, P. B. Thapa, K. G. Meador, K. Hall, and K. T. Murray, “Antipsychotics and the risk of sudden cardiac death,” Archives of General Psychiatry, vol. 58, no. 12, pp. 1161–1167, 2001. View at Scopus
  2. C. Enger, L. Weatherby, R. F. Reynolds, D. B. Glasser, and A. M. Walker, “Serious cardiovascular events and mortality among patients with schizophrenia,” Journal of Nervous and Mental Disease, vol. 192, no. 1, pp. 19–27, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Schneeweiss, S. Setoguchi, A. Brookhart, C. Dormuth, and P. S. Wang, “Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients,” CMAJ, vol. 176, no. 5, pp. 627–632, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. W. A. Ray, C. P. Chung, K. T. Murray, K. Hall, and C. M. Stein, “Atypical antipsychotic drugs and the risk of sudden cardiac death,” The New England Journal of Medicine, vol. 360, no. 3, pp. 225–235, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. P. M. Haddad and S. G. Sharma, “Adverse effects of atypical antipsychotics: differential risk and clinical implications,” CNS Drugs, vol. 21, no. 11, pp. 911–936, 2007. View at Scopus
  6. L. Kuller, A. Lilienfeld, and R. Fisher, “An epidemiological study of sudden and unexpected deaths in adults,” Medicine, vol. 46, no. 4, pp. 341–361, 1967. View at Scopus
  7. R. Manfredini, F. Portaluppi, E. Grandi, C. Fersini, and M. Gallerani, “Out-of-hospital sudden death referring to an emergency department,” Journal of Clinical Epidemiology, vol. 49, no. 8, pp. 865–868, 1996. View at Publisher · View at Google Scholar · View at Scopus
  8. C. M. Albert, J. Ma, N. Rifai, M. J. Stampfer, and P. M. Ridker, “Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death,” Circulation, vol. 105, no. 22, pp. 2595–2599, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. S. G. Priori, E. Aliot, C. Blomstrom-Lundqvist et al., “Task force on sudden cardiac death of the european society of cardiology,” European Heart Journal, vol. 23, no. 3, p. 257, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Schatzkin, L. A. Cupples, and T. Heeren, “Sudden death in the Framingham heart study: differences in incidence and risk factors by sex and coronary disease status,” American Journal of Epidemiology, vol. 120, no. 6, pp. 888–899, 1984. View at Scopus
  11. W. B. Kannel and A. Schatzkin, “Sudden death: lessons from subsets in population studies,” Journal of the American College of Cardiology, vol. 5, no. 6, pp. 141B–149B, 1985. View at Scopus
  12. G. Wannamethee, A. G. Shaper, P. W. Macfarlane, and M. Walker, “Risk factors for sudden cardiac death in middle-aged British men,” Circulation, vol. 91, no. 6, pp. 1749–1756, 1995. View at Scopus
  13. L. G. Escobedo and M. M. Zack, “Comparison of sudden and nonsudden coronary deaths in the United States,” Circulation, vol. 93, no. 11, pp. 2033–2036, 1996. View at Scopus
  14. D. P. J. Osborn, G. Levy, I. Nazareth, I. Petersen, A. Islam, and M. B. King, “Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Research Database,” Archives of General Psychiatry, vol. 64, no. 2, pp. 242–249, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Dixon, L. Postrado, J. Delahanty, P. J. Fischer, and A. Lehman, “The association of medical comorbidity in schizophrenia with poor physical and mental health,” Journal of Nervous and Mental Disease, vol. 187, no. 8, pp. 496–502, 1999. View at Publisher · View at Google Scholar · View at Scopus
  16. S. M. Curkendall, J. Mo, D. B. Glasser, M. R. Stang, and J. K. Jones, “Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada,” Journal of Clinical Psychiatry, vol. 65, no. 5, pp. 715–720, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Williams, T. P. van Staa, S. Puri, and S. Eaton, “Recent advances in the utility and use of the General Practice Research Database as an example of a UK Primary Care Data resource,” Therapeutic Advances in Drug Safety, vol. 3, pp. 89–99, 2012. View at Publisher · View at Google Scholar
  18. E. Herrett, S. L. Thomas, W. M. Schoonen, L. Smeeth, and A. J. Hall, “Validation and validity of diagnoses in the General Practice Research Database: a systematic review,” British Journal of Clinical Pharmacology, vol. 69, no. 1, pp. 4–14, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Hennessy, C. E. Leonard, C. P. Freeman et al., “Validation of diagnostic codes for outpatient-originating sudden cardiac death and ventricular arrhythmia in Medicaid and Medicare claims data,” Pharmacoepidemiology and Drug Safety, vol. 19, no. 6, pp. 555–562, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. D. M. Gardner, A. L. Murphy, H. O'Donnell, F. Centorrino, and R. J. Baldessarini, “International consensus study of antipsychotic dosing,” American Journal of Psychiatry, vol. 167, no. 6, pp. 686–693, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. D. W. Hosmer and S. Lemeshow, Applied Logistic Regression, John Wiley and Sons, New York, NY, USA, 2nd edition, 2000.
  22. E. Vittinghoff and C. E. McCulloch, “Relaxing the rule of ten events per variable in logistic and cox regression,” American Journal of Epidemiology, vol. 165, no. 6, pp. 710–718, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Ramlau-Hansen, “Smoothing counting process intensities by means of kernel functional,” Annals of Statistics, vol. 11, no. 2, pp. 453–466, 1983. View at Publisher · View at Google Scholar
  24. E. H. Høyer, P. B. Mortensen, and A. V. Olesen, “Mortality and causes of death in a total national sample of patients with affective disorders admitted for the first time between 1973 and 1993,” British Journal of Psychiatry, vol. 176, pp. 76–82, 2000. View at Publisher · View at Google Scholar · View at Scopus
  25. T. S. Stroup, J. A. Lieberman, J. P. McEvoy et al., “Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study,” American Journal of Psychiatry, vol. 164, no. 3, pp. 415–427, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. L. S. Schneider, K. S. Dagerman, and P. Insel, “Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials,” Journal of the American Medical Association, vol. 294, no. 15, pp. 1934–1943, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. S. S. Gill, S. E. Bronskill, S.-L. T. Normand et al., “Antipsychotic drug use and mortality in older adults with dementia,” Annals of Internal Medicine, vol. 146, no. 11, pp. 775–786, 2007. View at Scopus
  28. S. Schneeweiss, S. Setoguchi, and A. Brookhart, “Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients,” CMAJ, vol. 176, no. 11, p. 1613, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Setoguchi, P. S. Wang, M. Alan Brookhart, C. F. Canning, L. Kaci, and S. Schneeweiss, “Potential causes of higher mortality in elderly users of conventional and atypical antipsychotic medications,” Journal of the American Geriatrics Society, vol. 56, no. 9, pp. 1644–1650, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. K. F. Huybrechts, T. Gerhard, S. Crystal et al., “Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: Population based cohort study,” BMJ, vol. 344, no. 7848, article e977, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. P. S. Wang, S. Schneeweiss, J. Avorn et al., “Risk of death in elderly users of conventional vs. atypical antipsychotic medications,” The New England Journal of Medicine, vol. 353, no. 22, pp. 2335–2341, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. G. Trifirò, K. M. C. Verhamme, G. Ziere, A. P. Caputi, B. H. C. Stricker, and M. C. J. M. Sturkenboom, “All-cause mortality associated with atypical and typical antipsychotics in demented outpatients,” Pharmacoepidemiology and Drug Safety, vol. 16, no. 5, pp. 538–544, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. M.-C. Bralet, V. Yon, G. Loas, and C. Noisette, “Mortality in schizophrenia: a 8-year follow-up study in 150 chronic schizophrenics,” Encephale, vol. 26, no. 6, pp. 32–41, 2000. View at Scopus
  34. V. Hansen, E. Arnesen, and B. K. Jacobsen, “Total mortality in people admitted to a psychiatric hospital,” British Journal of Psychiatry, vol. 170, pp. 186–190, 1997. View at Scopus
  35. D. W. Black, “Iowa record-linkage study: death rates in psychiatric patients,” Journal of Affective Disorders, vol. 50, no. 2-3, pp. 277–282, 1998. View at Publisher · View at Google Scholar · View at Scopus
  36. D. N. Baxter, “The mortality experience of individuals on the Salford Case Register: I. all-cause mortality,” British Journal of Psychiatry, vol. 168, pp. 772–779, 1996. View at Scopus
  37. P. Corten, M. Ribourdouille, and M. Dramaix, “Premature death among outpatients at a community mental health center,” Hospital and Community Psychiatry, vol. 42, no. 12, pp. 1248–1251, 1991. View at Scopus
  38. E. L. Idler, “Age differences in self-assessments of health: age changes, cohort differences, or survivorship?” Journals of Gerontology, vol. 48, no. 6, pp. S289–S300, 1993. View at Scopus
  39. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinology, North American Association for the Study of Obesity, “Consensus development conference on antipsychotic drugs and obesity and diabetes,” Diabetes Care, vol. 27, no. 2, pp. 596–601, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. J. Langan and P. Shajahan, “Antipsychotic polypharmacy: review of mechanisms, mortality and management,” Psychiatrist, vol. 34, no. 2, pp. 58–62, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Ilyas and J. Moncrieff, “Trends in prescriptions and costs of drugs for mental disorders in England, 1998–2010,” British Journal of Psychiatry, vol. 200, no. 5, pp. 393–398, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. National Institute for Clinical Excellence, 2002, Guidance on the use of newer (atypical) antipsychotic agents for the treatment of schizophrenia- [TA43 ].
  43. D. King and M. Knapp, “Patterns of, and factors associated with, atypical and typical antipsychotic prescribing by general practitioners in the UK during the 1990s,” Journal of Mental Health, vol. 15, no. 3, pp. 269–278, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Hennessy, C. E. Leonard, C. M. Palumbo, W. B. Bilker, C. Newcomb, and S. E. Kimmel, “Diagnostic codes for sudden cardiac death and ventricular arrhythmia functioned poorly to identify outpatient events in EPIC's General Practice Research Database,” Pharmacoepidemiology and Drug Safety, vol. 17, no. 12, pp. 1131–1136, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. B. F. Hoffman and K. H. Dangman, “The role of antiarrhythmic drugs in sudden cardiac death,” Journal of the American College of Cardiology, vol. 8, no. 1, pp. 104A–109A, 1986. View at Scopus
  46. J. C. Doig, “Drug-induced cardiac arrhythmias. Incidence, prevention and management,” Drug Safety, vol. 17, no. 4, pp. 265–275, 1997. View at Scopus
  47. W. V. R. Vieweg and M. A. Wood, “Tricyclic antidepressants, QT interval prolongation, and torsade de pointes,” Psychosomatics, vol. 45, no. 5, pp. 371–377, 2004. View at Publisher · View at Google Scholar · View at Scopus
  48. K. Bingefors, D. Isacson, L. Von Knorring, B. Smedby, and K. Wicknertz, “Antidepressant-treated patients in ambulatory care mortality during a nine-year period after first treatment,” British Journal of Psychiatry, vol. 169, no. 5, pp. 647–654, 1996. View at Scopus
  49. J. Ryan, I. Carriere, K. Ritchie et al., “Late-life depression and mortality: influence of gender and antidepressant use,” British Journal of Psychiatry, vol. 192, no. 1, pp. 12–18, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. W. Whang, L. D. Kubzansky, I. Kawachi et al., “Depression and risk of sudden cardiac death and coronary heart disease in women. Results from the Nurses' Health Study,” Journal of the American College of Cardiology, vol. 53, no. 11, pp. 950–958, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. W. A. Ray, K. T. Murray, S. Meredith, S. S. Narasimhulu, K. Hall, and C. M. Stein, “Oral erythromycin and the risk of sudden death from cardiac causes,” The New England Journal of Medicine, vol. 351, no. 11, pp. 1089–1159, 2004. View at Publisher · View at Google Scholar · View at Scopus
  52. J. A. Staffa, J. K. Jones, C. B. Gable, J. P. Verspeelt, and W. K. Amery, “Risk of selected serious cardiac events among new users of antihistamines,” Clinical Therapeutics, vol. 17, no. 6, pp. 1062–1077, 1995. View at Publisher · View at Google Scholar · View at Scopus
  53. F. J. De Abajo and L. A. Rodríguez, “Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs,” British Journal of Clinical Pharmacology, vol. 47, no. 3, pp. 307–313, 1999. View at Publisher · View at Google Scholar · View at Scopus